HUP0202495A2 - Orális alkalmazásra szolgáló stabil gyógyszerkészítmény - Google Patents

Orális alkalmazásra szolgáló stabil gyógyszerkészítmény

Info

Publication number
HUP0202495A2
HUP0202495A2 HU0202495A HUP0202495A HUP0202495A2 HU P0202495 A2 HUP0202495 A2 HU P0202495A2 HU 0202495 A HU0202495 A HU 0202495A HU P0202495 A HUP0202495 A HU P0202495A HU P0202495 A2 HUP0202495 A2 HU P0202495A2
Authority
HU
Hungary
Prior art keywords
active ingredient
oxide
oral use
matrix
iii
Prior art date
Application number
HU0202495A
Other languages
English (en)
Inventor
Kazuhiro Sako
Toyohiro Sawada
Shunsuke Watanabe
Keiichi Yoshihara
Tatsunobu Yoshioka
Original Assignee
Yamanouchi Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22520720&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0202495(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yamanouchi Pharmaceutical Co., Ltd. filed Critical Yamanouchi Pharmaceutical Co., Ltd.
Publication of HUP0202495A2 publication Critical patent/HUP0202495A2/hu
Publication of HUP0202495A3 publication Critical patent/HUP0202495A3/hu
Publication of HU229295B1 publication Critical patent/HU229295B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Abstract

A találmány tárgya orális alkalmazásra szolgáló stabilgyógyszerkészítmény és ezek előállítása, amelyben megakadályozzák aváltozásokat a hatóanyag-felszabadulási profilban a tárolás során mégmegvilágítás esetén is, ahol ezt sárga vas(III)oxid és/vagy vörösvas(III)oxid adagolásával érik el a hatóanyagot, hidrofil alapanyagotés polietilén-oxidot tartalmazó mátrix-típusú, nyújtott hatóanyag-leadású készítményben. A találmány tárgya továbbá eljárás a hatóanyag-felszabadulási profilban bekövetkező változások megakadályozására atárolás során megvilágítás esetén a hatóanyagot, hidrofil alapanyagotés polietilén-oxidot tartalmazó mátrix típusú, nyújtott hatóanyag-leadású készítményekben. A kapott termék minőségbiztonságára vonatkozóidőtartama meghosszabbítható és a termék értéke javítható atalálmánynak megfelelően. Ó
HU0202495A 1999-08-04 2000-08-01 Stable medicinal compositions for oral use HU229295B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14722299P 1999-08-04 1999-08-04
PCT/JP2000/005075 WO2001010466A1 (fr) 1999-08-04 2000-08-01 Compositions medicinales stables pour administration orale

Publications (3)

Publication Number Publication Date
HUP0202495A2 true HUP0202495A2 (hu) 2002-11-28
HUP0202495A3 HUP0202495A3 (en) 2004-05-28
HU229295B1 HU229295B1 (en) 2013-10-28

Family

ID=22520720

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202495A HU229295B1 (en) 1999-08-04 2000-08-01 Stable medicinal compositions for oral use

Country Status (17)

Country Link
EP (1) EP1205190B1 (hu)
JP (1) JP3462490B2 (hu)
KR (1) KR100507400B1 (hu)
CN (1) CN1193792C (hu)
AT (1) ATE324909T1 (hu)
AU (1) AU769807B2 (hu)
CA (1) CA2387705C (hu)
DE (1) DE60027728T2 (hu)
DK (1) DK1205190T3 (hu)
ES (1) ES2262528T3 (hu)
HU (1) HU229295B1 (hu)
MX (1) MXPA02001267A (hu)
NO (1) NO331834B1 (hu)
PL (1) PL200645B1 (hu)
PT (1) PT1205190E (hu)
RU (1) RU2220715C2 (hu)
WO (1) WO2001010466A1 (hu)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003090743A1 (en) * 2002-04-24 2003-11-06 Cypress Bioscience, Inc. Prevention and treatment of functional somatic disorders, including stress-related disorders
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
ZA200409537B (en) * 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
JP2005162736A (ja) * 2003-11-10 2005-06-23 Astellas Pharma Inc 徐放性医薬組成物
JP2005162737A (ja) * 2003-11-10 2005-06-23 Astellas Pharma Inc 徐放性医薬組成物
US7358270B2 (en) 2004-01-30 2008-04-15 Astellas Pharma Inc. Treating agent for irritable bowel syndrome
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
JP4632204B2 (ja) * 2005-09-21 2011-02-16 アステラス製薬株式会社 下痢型過敏性腸症候群治療剤
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
US20110300209A1 (en) * 2009-01-20 2011-12-08 Micro Labs Limited Modified release solid pharmaceutical compositions of trimetazidine and process thereof
ES2534908T3 (es) 2009-07-22 2015-04-30 Grünenthal GmbH Forma de dosificación de liberación controlada extruida por fusión en caliente
CN102639118B (zh) 2009-07-22 2015-07-29 格吕伦塔尔有限公司 氧化稳定的抗干扰剂型
EP2554168B1 (en) 2010-03-29 2018-01-24 Astellas Pharma Inc. Controlled release pharmaceutical composition
PL2611426T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Postać dawkowania zawierająca nieorganiczne sole, odporna na zgniatanie
KR102027912B1 (ko) 2011-02-15 2019-10-02 지엘팜텍주식회사 경구투여용 탐술로신 또는 이의 약제학적으로 허용되는 염을 포함하는 서방성 삼중정제
DK2736495T3 (da) 2011-07-29 2017-11-13 Gruenenthal Gmbh Misbrugsbestandig tablet som tilvejebringer øjeblikkelig frigivelse af lægemiddel
RS56527B1 (sr) 2011-07-29 2018-02-28 Gruenenthal Gmbh Tableta za trenutno oslobađanje leka rezistentna na zloupotrebu
MX362357B (es) 2012-04-18 2019-01-14 Gruenenthal Gmbh Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis.
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
BR112016010482B1 (pt) 2013-11-26 2022-11-16 Grünenthal GmbH Preparação de uma composição farmacêutica em pó por meio de criomoagem
MX2016014738A (es) 2014-05-12 2017-03-06 Gruenenthal Gmbh Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
CN106456550A (zh) 2014-05-26 2017-02-22 格吕伦塔尔有限公司 避免乙醇剂量倾泻的多颗粒
EP3437639A1 (en) * 2015-03-19 2019-02-06 Daiichi Sankyo Company, Limited Solid preparation containing colorant
EP3272345B1 (en) 2015-03-19 2019-10-16 Daiichi Sankyo Company, Limited Solid preparation containing antioxidant agent
CA2983642A1 (en) 2015-04-24 2016-10-27 Grunenthal Gmbh Tamper-resistant dosage form with immediate release and resistance against solvent extraction
TWI722988B (zh) 2015-06-05 2021-04-01 瑩碩生技醫藥股份有限公司 緩釋性醫藥組合物及其製備方法
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
EP3489224A1 (en) 2017-02-14 2019-05-29 Alfred E. Tiefenbacher (GmbH & Co. KG) Mirabegron prodrugs
EP3722285B1 (en) 2020-04-08 2022-03-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Process for preparing mirabegron enacarbil

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL194389C (nl) * 1984-06-14 2002-03-04 Novartis Ag Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager.
US4859470A (en) * 1988-06-02 1989-08-22 Alza Corporation Dosage form for delivering diltiazem
HU206824B (en) * 1990-08-24 1993-01-28 Biogal Gyogyszergyar Process for the production of a table crystallizing in the monoclinic system, which contains light-, heat-, and moisture- sensitive active agents
JP2820829B2 (ja) * 1991-03-07 1998-11-05 武田薬品工業株式会社 有核散剤およびその製造方法
JPH04346929A (ja) * 1991-05-22 1992-12-02 Takada Seiyaku Kk 光に安定なメシル酸ブロモクリプチン製剤
DE69619979T2 (de) * 1995-04-14 2002-11-21 Pharma Pass Illkirch Graffenst Feste zusammensetzungen mit einem nicht-amorphem wirkstoff und polyäthylenoxyd
WO1999006045A1 (en) * 1997-08-01 1999-02-11 Elan Corporation, Plc Controlled release pharmaceutical compositions containing tiagabine
ATE241341T1 (de) * 1997-09-10 2003-06-15 Takeda Chemical Industries Ltd Stabilisierte pharmazeutische zusammensetzung

Also Published As

Publication number Publication date
EP1205190A4 (en) 2004-01-21
HUP0202495A3 (en) 2004-05-28
NO20020516D0 (no) 2002-02-01
DE60027728D1 (de) 2006-06-08
MXPA02001267A (es) 2002-08-12
PL200645B1 (pl) 2009-01-30
DK1205190T3 (da) 2006-08-14
HU229295B1 (en) 2013-10-28
CA2387705A1 (en) 2001-02-15
KR100507400B1 (ko) 2005-08-10
ATE324909T1 (de) 2006-06-15
JP3462490B2 (ja) 2003-11-05
AU6182100A (en) 2001-03-05
DE60027728T2 (de) 2007-04-26
KR20020046277A (ko) 2002-06-20
PL353154A1 (en) 2003-10-20
CN1373673A (zh) 2002-10-09
CN1193792C (zh) 2005-03-23
NO331834B1 (no) 2012-04-16
CA2387705C (en) 2009-06-30
PT1205190E (pt) 2006-09-29
EP1205190A1 (en) 2002-05-15
NO20020516L (no) 2002-02-01
AU769807B2 (en) 2004-02-05
EP1205190B1 (en) 2006-05-03
RU2220715C2 (ru) 2004-01-10
WO2001010466A1 (fr) 2001-02-15
ES2262528T3 (es) 2006-12-01

Similar Documents

Publication Publication Date Title
HUP0202495A2 (hu) Orális alkalmazásra szolgáló stabil gyógyszerkészítmény
HUP0203451A2 (hu) Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra
HUP0402293A2 (hu) Fexofenadint tartalmazó szájban diszpergálódó tablettakészítmény, bevonatos granulátum és eljárás az előállítására
TW200503775A (en) Pharmaceutical composition and method for treating
HK1039572A1 (en) Flash-melt oral dosage formulation
YU69603A (sh) Atorvastatin kalcijum u farmaceutskom obliku, njegovoj smeši i farmaceutskoj formulaciji, koja sadrži atorvastatin kalcijum
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
DE60121301D1 (de) Flibanserin zur Behandlung extrapyramidaler Bewegungsstörungen
HUP0204451A2 (hu) Nimesulidot tartalmazó szabályozott hatóanyag-leadású készítmények
EP1750862A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING IRBESARTAN
MY127350A (en) Flash-melt oral dose formulations
SE0102843D0 (sv) Stabilized oral pharmaceutical composition containing lodide and lodate and method
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
ATE430561T1 (de) Chronotherapeutische diltiazem formulierungen und deren verabreichung
DE60006362D1 (de) Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen
MY137570A (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis crohn's disease
WO1999047172A3 (en) Oral pharmaceutical compositions to be taken without liquids, which contain inclusion complexes
GEP20043377B (en) Pharmaceutical Complex
WO2004032843A3 (en) Mucoadhesive tetracycline formulations
TR200103473T2 (tr) Kristalli azabisiklo (2.2.2) oktan-3-amin sitratin polimorfları ve farmasötik kompozisyonları.
UA79567C2 (en) Orodispersible pharmaceutical composition of antithrombolic compound
CA2492470A1 (en) Stable pharmaceutical composition comprising erythropoietin
PT1603559E (pt) Composição farmacêutica para acidificação intracelular com cis-urocânico
ATE331509T1 (de) Zusammensetzung die paracetamol und niflumic säure enthält
IT1252599B (it) Composizione farmaceutica effervescente anticefalalgica